Unveiling molecular insights: in silico exploration of TLR4 antagonist for management of dry eye syndrome
Background Dry eye disease is the most commonplace multifractional ocular complication, which has already affected millions of people in the world. It is identified by the excessive buildup of reactive oxygen species, leading to substantial corneal epithelial cell demise and ocular surface inflammat...
Saved in:
Main Authors: | Kothandan Sudhakar, Neeru Dugar, Srikanth Jupudi, Ravichandran Ashwin, Kuppusamy Gowthamarajan |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-05-01
|
Series: | BMJ Open Ophthalmology |
Online Access: | https://bmjophth.bmj.com/content/9/1/e001610.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comment on efficacy, safety, and tolerability of Lifitegrast 5% eye drops: A randomized, double-blind, active-controlled trial in Indian patients with dry eye disease
by: Krishnagopal Srikanth, et al.
Published: (2025-01-01) -
NPT1220-312, a TLR2/TLR9 Small Molecule Antagonist, Inhibits Pro-Inflammatory Signaling, Cytokine Release, and NLRP3 Inflammasome Activation
by: Agata Habas, et al.
Published: (2022-01-01) -
Unveiling the biological activities of Heliotropium indicum L. plant extracts: anti-inflammatory activities, GC–MS analysis, and in-silico molecular docking
by: Mst. Sadia Afroz Shoily, et al.
Published: (2025-01-01) -
Eyes Open on Sleep and Wake: In Vivo to In Silico Neural Networks
by: Amaury Vanvinckenroye, et al.
Published: (2016-01-01) -
Clinical experience with cyclosporine eye drops for severe dry eye
by: O.I. Lebedev, et al.
Published: (2019-04-01)